Skip to contentC
China Pharma Holdings, Inc.
C
CPHIChina Pharma Holdings, Inc. Q4 2022 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$2.92M$2.92Mderived+1.1% vs Q4 2021 Net Income-$1.26M-$1.26MderivedN/M vs Q4 2021 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
China Pharma Holdings, Inc. · CIK 1106644 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$42,682−85.9% Operating Incomederived-$1,169,012N/M Operating Cash Flowderived$584,594N/M Free Cash Flowderived$611,862N/M Margins · derivedGross margin1.5%−9.0 pt vs Q4 2021
Operating margin-40.0%−17.6 pt vs Q4 2021
Net margin-43.3%−9.3 pt vs Q4 2021
ended Dec 31, 2022 · filed Mar 30, 2023 · 89 d after period end